Table 1 Clinical factors of LS-SCLC patients

Sex

0.859

0.704

 Male

152

76.0%

 Female

48

24.0%

Age

200

23–81(year)

0.051

0.147

Smoking Status

0.020

0.010

 Yes

147

73.5%

 No

53

26.5%

KPS

0.109

0.106

 ≤ 70

6

3.0%

 80

97

48.5%

 85

2

1.0%

 90

85

42.5%

 100

10

5.0%

T

0.009

0.023

 1

28

14.5%

 2

79

40.9%

 3

54

28.0%

 4

30

15.5%

N

0.607

0.146

 0

7

3.6%

 1

12

6.2%

 2

130

67.4%

 3

43

22.2%

M

 0

200

100.0%

 1

0

0

Radiotherapy technology

0.464

0.975

 IMRT

139

69.5%

 VMAT

61

30.5%

Dose(Gy)

 < 0.001

 < 0.001

 GTV60

57

28.5%

 PGTV60,PTV 54

143

71.5%

Cycles of Neoadjuvant chemotherapy ≥ 2

0.796

0.478

 Yes

177

83.5%

 No

23

16.5%

Concurrent chemotherapy

0.215

0.224

 Yes

117

58.5%

 No

83

41.5%

Consolidation chemotherapy

0.205

0.094

 Yes

116

58.0%

 No

84

42.0%

Pro-GRP

200

10.8–5000

 < 0.001

 < 0.001